About Andrew R. Garbarino
Andrew R. Garbarino is a Republican U.S. Representative from New York serving in the House of Representatives for the term beginning January 3, 2025. Born September 27, 1984, he represents a Long Island district and serves on the House Committee on Homeland Security, the House Committee on Financial Services, and the House Committee on Ethics. His Financial Services assignments include the Subcommittee on Oversight and Investigations and the Subcommittee on Capital Markets, Housing, and Insurance.
Garbarino has disclosed 11 stock trades with an estimated total trading volume of about $0.1 million, placing him among the less active congressional traders. His most frequently traded stocks include Oramed Pharmaceuticals (ORMP) with 3 trades, followed by OneSpaWorld Holdings (OSW) and Tellurian (TELL) with 2 trades each. Additional activity includes single trades in Bank of America (BAC) and Gold Standard Ventures (GSS). His transactions show a near-even split between purchases and sales, with 5 buys and 6 sells.
Andrew R. Garbarino's Trades
Trading Activity
| Date | Asset | Type | Amount |
|---|---|---|---|
| 2025-08-21 | GAP | sell | $1K-$15K |
| 2022-01-14 | TELL | buy | $1K-$15K |
| 2022-01-14 | ORMP | sell | $1K-$15K |
| 2021-10-01 | TELL | buy | $1K-$15K |
| 2021-10-01 | ORMP | sell | $1K-$15K |
| 2021-10-01 | OSW | sell | $1K-$15K |
| 2021-10-01 | GPS | buy | $1K-$15K |
| 2021-06-07 | VMCCXFUND | buy | $1K-$15K |
| 2021-06-03 | New World NEWFXFUND | sell | $1K-$15K |
| 2021-06-03 | New Perspective ANWPXFUND | sell | $1K-$15K |
| 2021-06-03 | Investment Company of America AIVSXFUND | sell | $1K-$15K |
| 2021-06-03 | Capital World Grow and IncomeFUND | sell | $1K-$15K |
| 2021-04-23 | ORMP | buy | $1K-$15K |
| 2021-04-23 | OSW | buy | $1K-$15K |
| 2021-04-23 | GSS | sell | $1K-$15K |
| 2021-04-23 | BAC | sell | $1K-$15K |
Estimated current holdings
Derived from disclosed buys minus sells at range midpoints. Positions opened before disclosure records began, or reported only in ranges, make this an estimate of direction and scale, not a brokerage statement.